Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 3/20 | 0.54 |
| ▸ | TP53 | P04637 | 3/20 | 0.54 |
| ▸ | CASP3 | P42574 | 3/20 | 0.52 |
| ▸ | MDM2 | Q00987 | 5/20 | 0.49 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2308310 | 1.00 | MDM4 (0.54) | MDM4TP53CASP3MDM2PIN1 | |
| SCHEMBL2308300 | 1.00 | MDM4 (0.54) | MDM4TP53CASP3MDM2PIN1 | |
| SCHEMBL2308312 | 1.00 | MDM4 (0.54) | MDM4TP53CASP3MDM2PIN1 | |
| SCHEMBL9186701 | 0.92 | MDM4 (0.59) | MDM4TP53CASP3MDM2KMT2A | |
| SCHEMBL8653785 | 0.92 | MDM4 (0.59) | MDM4TP53CASP3MDM2KMT2A | |
| SCHEMBL8653790 | 0.92 | MDM4 (0.59) | MDM4TP53CASP3MDM2KMT2A | |
| SCHEMBL8654704 | 0.92 | MDM4 (0.59) | MDM4TP53CASP3MDM2KMT2A | |
| SCHEMBL16744152 | 0.87 | CASP3 (0.55) | MDM4TP53CASP3MDM2KMT2A | |
| SCHEMBL8227090 | 0.87 | CASP3 (0.55) | MDM4TP53CASP3MDM2KMT2A | |
| SCHEMBL8234371 | 0.87 | CASP3 (0.55) | MDM4TP53CASP3MDM2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9345789-B2 | Specific inhibitors and active site probes for legumain | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2016-05-24 | — | — | US | disclosed |
| US-9345789-B2 | Specific inhibitors and active site probes for legumain | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2016-05-24 | — | — | US | disclosed |
| US-8895231-B2 | Patterning process and resist composition | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2014-11-25 | — | — | US | disclosed |
| US-8895231-B2 | Patterning process and resist composition | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2014-11-25 | — | — | US | disclosed |
| US-20120251459-A1 | SPECIFIC INHIBITORS AND ACTIVE SITE PROBES FOR LEGUMAIN | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2012-10-04 | — | — | US | disclosed |
| US-20120251459-A1 | SPECIFIC INHIBITORS AND ACTIVE SITE PROBES FOR LEGUMAIN | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2012-10-04 | — | — | US | disclosed |
| US-20120058428-A1 | PATTERNING PROCESS AND RESIST COMPOSITION | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2012-03-08 | — | — | US | disclosed |
| US-20120058428-A1 | PATTERNING PROCESS AND RESIST COMPOSITION | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2012-03-08 | — | — | US | disclosed |
| US-20080076824-A1 | modified glycinamides: Valine-alphahydroxy-glycinamide | CHRONTECH PHARMA AB (SE) | 2008-03-27 | — | — | US | disclosed |
| US-20080076824-A1 | modified glycinamides: Valine-alphahydroxy-glycinamide | CHRONTECH PHARMA AB (SE) | 2008-03-27 | — | — | US | disclosed |
| US-5629293-A | Single chain peptide compounds having hemoregulatory activity | NYCOMED IMAGING AS (NO) | 1997-05-13 | — | — | US | disclosed |
| EP-0643725-A1 | SINGLE CHAIN PEPTIDE COMPOUNDS HAVING HEMOREGULATORY ACTIVITY | NYCOMED IMAGING AS (NO) | 1995-03-22 | — | — | EP | disclosed |
| WO-1993024524-A1 | SINGLE CHAIN PEPTIDE COMPOUNDS HAVING HEMOREGULATORY ACTIVITY | HAFSLUND NYCOMED AS (NO) | 1993-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076824-A1 | modified glycinamides: Valine-alphahydroxy-glycinamide | GALE, ENGASE, UGGT1 | MDM4 1166/4885TP53 1635/4885CASP3 2910/4885 |
| US-20120251459-A1 | SPECIFIC INHIBITORS AND ACTIVE SITE PROBES FOR LEGUMAIN | ENGASE, LGMN, DNPEP | MDM4 3624/4885TP53 1981/4885CASP3 1732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.